| |
AZA
|
MMF
|
No IS
|
|---|
| |
n= 30
|
%
|
n= 39
|
%
|
n= 38
|
%
|
|---|
|
Medication
a
| | | | | | |
|
Prednisone
|
26
|
87
|
38
|
97
|
14
|
37
|
|
mg/day, median (range)
|
5.0 (0-50) §§§
| |
5.0 (0-30)###
| |
0 (0-20)§§§ ###
| |
|
Hydroxychloroquine
|
17
|
57
|
26
|
67
|
29
|
76
|
|
Manifestations
a
| | | | | | |
|
Nephritis
|
20
|
67
|
35
|
90
|
13
|
34
|
|
Proliferative class III, IV of all biopsy results available
|
12
|
75
|
22
|
76
|
3
|
38
|
|
CRF grade III+
|
5
|
25
|
6
|
17
|
1
|
8
|
|
Nephritis in remission
|
9
|
45
|
20
|
57
|
7
|
58
|
|
Active nephritis
|
11
|
55
|
15
|
43
|
6
|
46
|
|
New nephritis
|
1
|
5
|
0
|
0
|
6
|
46
|
|
Arthritis
|
3
|
10
|
2
|
5
|
9
|
24
|
|
Serositis
|
1
|
3
|
0
|
0
|
4
|
11
|
|
Myositis
|
2
|
7
|
1
|
3
|
0
|
0
|
|
CNS
|
1
|
3
|
0
|
0
|
1
|
3
|
|
Vasculitis
|
1
|
3
|
1
|
3
|
1
|
3
|
|
Flares
a
|
14
|
47
|
9
|
23
|
12
|
32
|
|
Lupus nephritis flare
|
10
|
71
|
4
|
44
|
6
|
50
|
|
CNS flare
|
0
|
0
|
0
|
0
|
1
|
3
|
|
Arthritis flare
|
0
|
0
|
2
|
22
|
5
|
42
|
|
Serositis flare
|
2
|
14
|
0
|
0
|
3
|
8
|
|
Myositis flare
|
1
|
7
|
1
|
11
|
0
|
0
|
|
Vasculitis flare
|
0
|
0
|
1
|
11
|
0
|
0
|
|
Ref. thrombocytopenia
|
0
|
0
|
1
|
11
|
0
|
0
|
|
ILD flare
|
1
|
7
|
0
|
0
|
0
|
0
|
|
Autoantibodies
a
| | | | | | |
|
Anti-dsDNA
|
27
|
90
|
36
|
92
|
28
|
74
|
|
C median, U/ml (range)
|
39 (0-1,250)
| |
29 (0-1,065)
| |
32 (0-1,496)
| |
|
Anti-Ro
|
17
|
57
|
16
|
41
|
24
|
65
|
|
Anti-La
|
8
|
27
|
6
|
15
|
10
|
27
|
|
Anti-U1RNP
|
11
|
37
|
14
|
36
|
20
|
54
|
|
Anti-SM
|
6
|
20
|
6
|
15
|
8
|
22
|
|
APLA/LA
|
10
|
33
|
14
|
38b
|
9
|
28b
|
|
Consumption of complement factors
a
|
15
|
50
|
16
|
41
|
15
|
39
|
|
SLEDAI
| | | | | | |
|
Median (range)
|
6 (0-18)
| |
4 (0-14)
| |
4 (0-24)
| |
- Results are presented as number and percent of patients unless otherwise stated. aResulting in an intensification of the immunosuppressive therapy (> 50mg prednisone-equivalent added, or switch of the therapy regimen to a more potent regimen, such as cyclophosphamide). AZA, azathioprine; MMF, mycophenolate mophetil; IS, immunosuppression; CRF, chronic renal failure; CNS, central nervous system; ILD, interstitial lung disease; APLA, anti-phospholipid antibodies; LA, lupus anticoagulant; SLEDAI, SLE disease activity index. bData incomplete (antibody status known in 37 and 32 patients respectively). Statistically significant differences detected between the dose of prednisone-equivalent, Dunn's Multiple Comparison test: #P < 0.05, ##P < 0.01, ###P < 0.001 statistically significant differences between patients taking MMF compared to patients without immunosuppressive therapy (no IS). §P < 0.05, §§P < 0.01, §§§P < 0.001 for statistically significant differences between patients taking AZA compared to patients without immunosuppressive therapy.
